Arctic Bioscience - Director's Dealing 2024

Arctic Bioscience - Mandatory notification of trade

Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in

Arctic Bioscience at an average price of NOK 1,72 per share. Following the

transaction, Christer Valderhaug holds 57,630 shares in Arctic Bioscience.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to

Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities

Trading Act § 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant